The Immunomodulator Platform
The immunomodulator platform is Gliknik's most clinically advanced program with two compounds in clinical safety testing in patients. Immunomodulators increase CD4, CD8, and antibody immune responses against targeted cancer epitopes. These peptide drugs are nearing completion of a Phase II dose-rising safety study in patients with very advanced Head and Neck Squamous Cell Carcinoma. Patients interested in learning more about the clinical trial should click here. Another Phase II clinical trial in combination with autologous T cell therapy for patients with advanced myeloma is also nearing complete enrollment. Patients interested in learning more about the clinical trial should click here. The company expects to assess these drugs for utility in other cancers.